

HOUSE BILL 629:

Physician Asst/Nurse Practit./STOP Act Clar.

2021-2022 General Assembly

Committee: Senate Health Care. If favorable, re-refer to **Date:** June 8, 2021

Rules and Operations of the Senate

Introduced by: Reps. Moffitt, Potts, Sasser, Adcock
Analysis of: First Edition

Prepared by: Jessica Boney
Staff Attorney

OVERVIEW: House Bill 629 would amend the conditions under which a physician assistant or a nurse practitioner are required to consult with the supervising physician when prescribing a targeted controlled substance.

CURRENT LAW: Under G.S. 90-18.1 and G.S. 90-18.2, a physician assistant or a nurse practitioner is required to consult with the supervising physician prior to prescribing a targeted controlled substance when all of the following conditions apply:

- The patient is being treated by a facility that primarily engages in the treatment of pain by prescribing narcotic medications or advertises in any medium for any type of pain management services.
- The therapeutic use of the targeted controlled substance will or is expected to exceed a period of 30 days.

BILL ANALYSIS:

Sections 1.(a) and 1.(b) would remove the circumstance when a patient is being treated by a facility that advertises in any medium for any type of pain management services from the conditions that require a physician assistant or a nurse practitioner to consult with the supervising physician prior to prescribing a targeted controlled substance.

EFFECTIVE DATE: This act would be effective October 1, 2021.

